Get the Stockscreener App
2.04
21.84%
-0.57
After Hours:
2.09
0.05
+2.45%
Indaptus Therapeutics Inc stock is traded at $2.04, with a volume of 272.53K.
It is down -21.84% in the last 24 hours and down -40.18% over the past month.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
See More
Previous Close:
$2.61
Open:
$2.56
24h Volume:
272.53K
Relative Volume:
0.29
Market Cap:
$271.81M
Revenue:
-
Net Income/Loss:
$-18.86M
P/E Ratio:
-0.1271
EPS:
-16.054
Net Cash Flow:
$-17.68M
1W Performance:
-17.07%
1M Performance:
-40.18%
6M Performance:
-17.74%
1Y Performance:
-79.44%
1-Day Range:
$2.02
$2.5601
1-Week Range:
$2.02
$2.925
52-Week Range:
$0.92
$10.57
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
2.04 | 347.76M | 0 | -18.86M | -17.68M | -16.05 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
Indaptus Therapeutics Inc (INDP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
INDP|Indaptus Therapeutics Inc|Price:2.610|Chg%:-0.160 - TradingKey
Indaptus Therapeutics Inc (INDP) Balance Sheet - TradingKey
Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Indaptus Therapeutics Inc (INDP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Indaptus Therapeutics Market Sentiment - Benzinga España
Indaptus Therapeutics Inc (INDP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Indaptus Therapeutics Inc (INDP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Indaptus Therapeutics, Inc. Revenue Breakdown – NASDAQ:INDP - TradingView
Indaptus Therapeutics Inc (INDP) Institutional Confidence - TradingKey
Indaptus Therapeutics Inc (NASDAQ: INDP) Share Price, INDP Stock News, INDP Share Price & Updates - Kalkine
Indaptus Therapeutics Inc (INDP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Indaptus Therapeutics (INDP) Q3 2025 earnings summary - Quartr
Indaptus Therapeutics, Inc. SEC Filing (Jul 20, 2026) - Stock Titan
Signal Proxy Intelligence Recommends Full Support for All Three Items at Indaptus Therapeutics, Inc. Annual Meeting - nrtoday.com
Indaptus Therapeutics (NASDAQ: INDP) seeks approval for 2026 equity plan - Stock Titan
Insider Traders Lose US$34k As Indaptus Therapeutics Drops - simplywall.st
INDP Q4 2025 Earnings: Wider-than-Expected Loss as Stock Declines Nearly 6%Revenue Estimate Trend - dars.gov.et
Indaptus Therapeutics Company Profile & Introduction - Moomoo
Indaptus Therapeutics (INDP) News Flow - Moomoo
INDP Q4 2025 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Surprise Score - dars.gov.et
Form 13D/A Indaptus Therapeutics For: 26 June By Investing.com - Investing.com Australia
Sino Lion Ventures (INDP) files amended 13D on 38,895,000 shares - Stock Titan
Indaptus Therapeutics (INDP) CEO details 8.44% common stock stake - Stock Titan
Indaptus (INDP) investor Ting Yang stake falls to 8.44% after share issuance - Stock Titan
Form S-3 Indaptus Therapeutics Inc For: 26 June By Investing.com - Investing.com South Africa
Indaptus Therapeutics (INDP) registers 18.864M shares; clinical program paused - Stock Titan
Revenue per share of Indaptus Therapeutics, Inc. – NASDAQ:INDP - TradingView
INDAPTUS THERAPEUTICSTO ISSUE 20 MLN SHARES AT $0.6 PER SHARESEC FILING - Moomoo
Indaptus TherapeuticsTo Issue 20 Million Shares At $0.6 Per ShareSEC Filing - TradingView
Indaptus Therapeutics Announces Private Placement of Common Stock - TipRanks
Indaptus Therapeutics (INDP) sells 20M shares in $12M Regulation S private placement - Stock Titan
Indaptus Therapeutics Raises $12 Million in Offshore Private Placement at $0.60 Per Share - TradingView
Form PRE 14A Sunshine Biopharma Inc For: 22 June By Investing.com - Investing.com Australia
Indaptus Therapeutics (INDP) asks shareholders to approve $300M PIPE, equity plan - Stock Titan
Indaptus Therapeutics Inc (INDP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Indaptus Therapeutics Inc (INDP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Top Cue Biopharma (CUE) Competitors 2026 - MarketBeat
Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders - Caledonian Record
Indaptus Therapeutics, Inc. announced that it expects to receive $12 million in funding - marketscreener.com
INDP Q4 2025 Earnings: EPS Misses Estimates Amid Continued R&D InvestmentSlow Growth Warning - dars.gov.et
12 Health Care Stocks Moving In Thursday's Intraday SessionAdial Pharmaceuticals (NASDAQ:ADIL), Aditxt - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
INDP Q4 2025 Earnings: EPS Misses Estimates, Stock Tumbles 42.62%Quarterly Earnings Report - newsline.com
Indaptus Therapeutics (INDP) Plunges 42% as Selling Pressure IntensifiesUp Down Volume - newsline.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):